Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus

The combination of lenvatinib, a multiple receptor tyrosine kinase inhibitor, plus everolimus, a mammalian target of rapamycin (mTOR) inhibitor, significantly improved clinical outcomes versus everolimus monotherapy in a phase II clinical study of metastatic renal cell carcinoma (RCC). We investigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuki, Masahiro, Adachi, Yusuke, Ozawa, Yoichi, Kimura, Takayuki, Hoshi, Taisuke, Okamoto, Kiyoshi, Tohyama, Osamu, Mitsuhashi, Kaoru, Yamaguchi, Atsumi, Matsui, Junji, Funahashi, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406533/
https://www.ncbi.nlm.nih.gov/pubmed/28107584
http://dx.doi.org/10.1111/cas.13169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406533/
https://www.ncbi.nlm.nih.gov/pubmed/28107584
http://dx.doi.org/10.1111/cas.13169

Ejemplares similares